Inoviq Ltd Resets Ovarian Cancer Test Path After Sample Quality Setback

INOVIQ resets EXO-OC development path after OC2200 sample-quality setback

In its 14 July 2026 investor webinar, INOVIQ (ASX: IIQ) detailed the outcome of its OC2200 clinical validation study for the EXO-OC ovarian cancer test and outlined the forward development strategy. Management was explicit that the study samples were unsuitable for a meaningful evaluation of test performance due to provider-related pre-analytical factors, not a failure of the test itself.

The company anchored several positives during the presentation. Earlier OC500 study data remains valid, the dual-path commercial strategy is unchanged, and INOVIQ reported cash of $9.35m at 30 June 2026, funding operations into 2027. A total of 1,255 case-control samples were analysed, with active partnering discussions underway for a US Laboratory Developed Test (LDT).

What happened with the OC2200 study

The OC2200 study was designed as a retrospective multi-provider case-control study. After the planned academic Biobank #1 (2,040 samples) was rejected in January 2026 for storage duration and volume issues, INOVIQ commenced alternative sourcing from five commercial biorepositories.

Management explained that the primary issue was biomarker variability between biorepositories, consistent with provider-specific pre-analytical factors and sample degradation. Critically, these differences could only be identified after the study was unblinded and initial data analysis was completed on 27 June 2026.

The technical review identified two key findings:

• CA125 was lower in OC2200 cancer samples, consistent with protein degradation.

• miRNA levels varied by biorepository, indicating provider-specific pre-analytical variation.

Understanding pre-analytical factors

Pre-analytical factors refer to everything that happens to a blood sample before the actual test is run: how blood is collected, handled, transported and stored. For exosome and miRNA-based blood tests, these steps directly affect biomarker integrity and, in turn, test accuracy.

Both are sensitive to sample handling, so inconsistent processing across different providers can distort the measured signal.

The presentation set out the sample journey that must be controlled at every stage:

1. Blood draw

2. Collection tube chemistry

3. Transport temperature and time

4. Sample processing (centrifugation)

5. Post-processing and platelet contamination

6. Storage temperature and freeze-thaw cycles

7. Downstream extraction, QC and analysis

Management emphasised that these factors can only be fully controlled in prospectively collected samples, the core lesson from OC2200. For investors, this reframes the outcome as a controllable process issue rather than a scientific failure, captured in the presentation’s phrase: “Correct sample collection = Correct test result.”

The underlying science still stands: OC500 results

The scientific evidence base supporting continued development comes from the earlier OC500 study (n=498), a retrospective case-control study using quality-controlled biobanked samples. These results, not the OC2200 outcome, underpin the company’s confidence in the EXO-OC test.

Under Model 1, tuned for screening in average-risk women, the OC500 study reported:

• ≥99.6% specificity

• 100% stage I/II sensitivity

• 77% all-stage sensitivity

A second model tuned for high-risk early detection reported 98% specificity, 92.3% stage I/II sensitivity and 92.5% all-stage sensitivity. According to the company, these OC500 results demonstrate that the test met screening performance criteria when applied to samples with controlled pre-analytical handling.

EXO-OC algorithm improvements applied to the original OC500 dataset lifted all-stage sensitivity from 77% to 92.5% at 98% specificity, with an International Patent Application covering EXO-OC biomarker combinations filed on 29 May 2026 to extend IP protection ahead of commercialisation.

Dual-path commercialisation strategy and next steps

INOVIQ confirmed its dual commercialisation paths remain unchanged. The company intends to commercialise the EXO-OC test initially as a Laboratory Developed Test (LDT) in the US for early detection of ovarian cancer in high-risk women, before further developing the test as an IVD for screening of average-risk women via the FDA Premarket Approval (PMA) pathway.

Management noted active discussions with potential partners to support technology transfer, assay optimisation and final validation of EXO-OC in a CLIA-certified laboratory. The next steps outlined include:

1. Complete the technical review to inform future validation studies

2. Refine and validate the EXO-OC biomarkers and algorithm

3. Source samples from a single-site biobank, nested prospective or real-world study with a collaborator, CRO or partner

4. Progress LDT partnering in the US

On the commercial opportunity, the presentation cited an LDT high-risk market of US$2.4–4.8B annual total addressable market in CLIA-only states, and an IVD screening opportunity with the potential to reach approximately 243M women across nine major markets.

Financial position and pipeline

INOVIQ reinforced its disciplined capital management. The company reported cash of $9.35m at 30 June 2026, with the OC2200 sample cost totalling $849k and FY26 project spend of $1.216m. INOVIQ stated it is funded into 2027.

On governance, management escalated the study findings to the Board, which is overseeing the technical review. No bonuses were paid in respect of FY25, and the company anticipates a similar bonus outcome for FY26 pending reviews to be completed at the end of October.

Beyond diagnostics, INOVIQ’s pipeline includes a CAR-exosome therapeutics programme at the pre-clinical stage, comprising EEV-001 (breast cancer), EEV-002 (lung cancer) and EEV-003 (ovarian cancer).

CAR-exosome preclinical data published in June 2026 showed CA125-targeting constructs killing more than 90% of OVCAR-3 and Caov-3 ovarian cancer cells within 48 hours, extending proof-of-concept to a third tumour type after earlier positive results in triple negative breast cancer and non-small cell lung cancer.

Board position on restoring shareholder value

While the recent study outcome was disappointing, the Board believes the underlying scientific rationale remains strong. By addressing the key development risks identified, strengthening future study design and execution, progressing commercial partnering opportunities and maintaining disciplined capital management, the company aims to reduce risk, accelerate value-creating milestones and deliver sustainable long-term shareholder value.

Summary and outlook

Closing the webinar, INOVIQ set out its stated priorities: complete EXO-OC development and validation, progress the test toward LDT-ready status and US laboratory partnering, accelerate the CAR-exosome programme, and maintain disciplined capital allocation.

The company reiterated that its commercial strategy is unchanged and that it remains funded to deliver upcoming catalysts in 2026. Management noted it is too early to quantify the precise impact on development timelines, with further updates to follow as key milestones are refined.

Don’t Miss the Next Healthcare Breakthrough on ASX

Big News Blast delivers FREE breaking ASX healthcare news directly to your inbox within minutes of release, complete with in-depth analysis. Over 20,000+ subscribers already stay ahead of the market with real-time alerts the moment announcements drop. Click the “Free Alerts” button at Big News Blast to make sure you never miss a market-moving update.